What Beauty Investors Look for in a Formulation Strategy
“A good formula does more than perform in the bottle. It can give a brand control, differentiation, margin flexibility and something valuable that survives beyond the original manufacturer.”
Investors don't invest in a cosmetic formula by itself.
They invest in a business.
Revenue growth, customer retention, margins, distribution, market opportunity, founder quality, brand strength, and operational execution can matter enormously. Current beauty investment commentary increasingly emphasizes durable unit economics, repeat purchasing, meaningful product differentiation, defensibility, and evidence that a brand can outlast the marketing moment that initially made it visible.
Formulation sits underneath several of those questions.
What does the brand actually own?
Can its hero product be reproduced consistently?
Is the product meaningfully different from what already exists?
Can margins improve as the company scales?
Is the company dependent on one manufacturer?
Are important claims supported?
Would an acquirer inherit a transferable product platform, or a collection of products it cannot fully control?
Those questions become increasingly important when a brand moves from selling products to becoming an asset another company might want to invest in or acquire.
What Do Beauty Investors Actually Look For?
There isn't one universal investor checklist.
A venture investor backing an early-stage beauty company may assess different risks from a private equity firm, strategic beauty conglomerate, family office, or acquirer evaluating an established brand.
But several themes appear repeatedly in current beauty investment discussions:
Strong and understandable consumer proposition
Product differentiation
Repeat purchasing and retention
Healthy unit economics
Scalability
Intellectual property or other defensibility
Operational discipline
Credible product claims
A path to profitable growth
In 2026, investors are showing particular interest in brands with clear value propositions, credible science or substantiation where relevant, customer retention, and product-level differentiation rather than relying exclusively on brand heat or viral acquisition.
Formulation can support almost every one of those areas.
It can't replace consumer demand.
But once the demand exists, the formulation strategy can help determine how durable and transferable the business behind that demand actually is.
Formulation Strategy Is Bigger Than the Ingredient List
A strong formulation strategy is not simply:
We use peptides.
Our moisturizer contains ceramides.
Our serum has 15% vitamin C.
Those statements describe product features.
A formulation strategy explains why the products are built the way they are and how that architecture creates an advantage for the business.
That may include decisions around:
Ingredient technology
Active levels
Product performance
Sensory differentiation
Claims
COGS
Ingredient sourcing
Supply-chain resilience
Manufacturing
Stability
Packaging
Product extensions
Formula ownership
A serious investor may never ask about the emulsifier system in your moisturizer.
They may care very much if that moisturizer represents 60% of your revenue and only one manufacturer has the information required to make it.
That is formulation strategy too.
Sales Get Attention. Defensibility Changes the Conversation.
A beauty brand can grow rapidly with products that are relatively easy to reproduce.
That does not invalidate the business.
Brand equity itself can be enormously valuable. Trademarks, trade dress, community, distribution, customer data, and brand identity may all contribute to investor or acquisition value. Industry legal and M&A commentary makes the same point: formulation ownership can be valuable, but it is one piece of a broader intellectual-property and defensibility picture.
Still, investors eventually ask:
Why can't someone else do this?
Sometimes the answer is the brand.
Sometimes it is patented technology.
Sometimes it is clinical evidence.
Sometimes it is a proprietary formulation system.
Sometimes it is manufacturing know-how.
Usually, the strongest answer is a combination.
The more easily the entire product can be copied, the harder the company may have to work elsewhere to maintain its competitive advantage.
Formula Ownership Becomes More Important During Due Diligence
Many founders assume that paying to develop a cosmetic formula means they own it.
That is not always true.
Ownership depends on the development arrangement and contract. Private-label formulas are generally controlled by the manufacturer or supplier. Custom-formulation agreements may transfer ownership, but only if the agreement actually provides for that transfer. Cosmeta's guide to Who Owns Your Cosmetic Formula? explores this distinction in detail.
From an investor or acquirer's perspective, the issue is straightforward:
What exactly is the company buying?
If the hero formula is owned by the brand, properly documented, and transferable, the company has one type of asset.
If the manufacturer owns it and the brand merely has the right to purchase finished goods, the acquirer is inheriting a supplier relationship.
Those can both support successful businesses.
They are not the same asset structure.
100% Quantitative Formula Ownership Creates a Different Kind of Control
Owning the finished quantitative formula can give a brand visibility into:
Every ingredient used
The percentage of each ingredient
Which commercial raw materials are specified
Which hero technologies are actually present
Which ingredients materially affect cost
Which portions of the formula may need future optimization
That matters for reasons that extend well beyond intellectual-property language.
It can give the company greater ability to:
Transfer manufacturing
Qualify alternate suppliers where technically appropriate
Respond to ingredient discontinuations
Optimize COGS
Modify the product for another market
Adapt to retailer standards
Upgrade ingredient technologies
Reformulate when regulations change
Maintain the product after an acquisition
This does not mean the brand owns a supplier's proprietary peptide, patented delivery technology, trademarked ingredient, or manufacturing IP simply because that technology appears inside the formula.
The brand owns the quantitative architecture it has the contractual rights to own.
Third-party intellectual property remains third-party intellectual property.
That distinction matters during sophisticated due diligence.
Portability May Matter as Much as Ownership
This is where I think the formulation conversation gets more interesting.
A founder may be able to say:
“Yes, we own the formula.”
Good.
Can it actually move?
A commercially portable formula requires more than a spreadsheet containing ingredient percentages.
An acquiring company may need sufficient information around:
Raw-material specifications
Approved suppliers
Processing requirements
Finished-product specifications
Stability history
Packaging compatibility
Manufacturing experience
Quality documentation
Testing
Claims support
Without that information, formula ownership may be legally clear but operationally less valuable.
This is a useful distinction:
Ownership tells you who controls the asset.
Portability tells you whether someone else can realistically use it.
An investor evaluating long-term manufacturing flexibility may care about both.
Manufacturer Dependence Is a Business Risk
A contract manufacturer can be an extraordinary partner.
The issue is not whether a brand uses outside manufacturing. Most beauty companies do.
The issue is concentration of control.
Imagine a brand where:
One manufacturer owns the formulas.
That manufacturer buys all raw materials.
The brand doesn't know exact percentages.
Stability records sit primarily with the manufacturer.
Supplier substitutions can occur with limited visibility.
Moving production would require reverse engineering the products.
That company may still have strong sales.
But operationally, a significant portion of the product business is dependent on one external relationship.
Now compare that with a brand that owns the formulas, maintains documentation, understands its critical raw materials, and can theoretically transfer production to another qualified manufacturer.
The second structure provides more optionality.
Investors like optionality because it reduces the number of things that can hold the entire company hostage.
A Great Manufacturer Should Not Have to Be a Permanent Single Point of Failure
There is an important nuance here.
Manufacturing relationships can themselves be valuable.
A manufacturer may have unusual capabilities, specialized equipment, low minimums, proprietary processes, strong quality systems, or excellent economics.
There may be good reasons to stay with them for decades.
The objective is not to move manufacturers for the sake of proving that you can.
The objective is to avoid building a business where you cannot move even if you need to.
Those are very different strategies.
A transferable formula gives the brand negotiating flexibility, continuity planning, and options during growth.
That becomes increasingly relevant as order volume increases.
Investors Care About Product Differentiation Because Growth Has to Last
Beauty is crowded.
A product can go viral because of:
Founder visibility
Social content
Creator adoption
Packaging
Celebrity association
Timing
Cultural relevance
Those can all be powerful growth engines.
Investors increasingly want evidence that the product itself can keep consumers coming back once the novelty fades. Current M&A commentary has emphasized repeat purchase, differentiation, durable profitability, and evidence that customers actually value the product beyond the viral moment.
This is where formulation can become one of the strongest retention tools a beauty company has.
The consumer may discover the brand because of marketing.
They repurchase because the product works well enough to earn another purchase.
Sensory Differentiation Is More Defensible Than It Looks
Beauty discussions about intellectual property tend to focus on patents.
But consumers do not evaluate products like patent attorneys.
They notice:
How quickly the cream absorbs
Whether the serum pills
How a cleanser rinses
Whether the moisturizer sits under makeup
Whether the product feels greasy
Whether the fragrance is distinctive
Whether the sunscreen leaves a cast
Whether the formula creates the exact finish they want
Those characteristics can become part of the product's identity.
They may not be formally patentable.
They can still be commercially valuable.
This is one reason I think sensory formulation is often underestimated during discussions about defensibility.
A competitor can copy an INCI list.
Reproducing the exact experience from that list is another matter.
An INCI List Is Not a Formula
This distinction becomes especially important in beauty due diligence.
The ingredient declaration tells you which ingredients are present and lists them according to applicable labeling rules.
It does not normally tell you:
Exact percentages
Supplier grades
Raw-material concentration
Processing
Ingredient addition sequence
Sensory architecture
Manufacturing conditions
How a proprietary blend is being used
Two products can therefore have extremely similar INCI lists and still feel or perform differently.
That doesn't make every formula impossible to copy.
It means the INCI declaration is not the quantitative product architecture.
Cosmeta's guide to What Is an INCI List? goes deeper into what an ingredient label does and does not reveal.
Investors May Care More About Repeatability Than Novelty
A highly innovative formula is exciting.
A highly innovative formula that cannot be manufactured consistently is a problem.
For an investor, the question eventually becomes:
Can this product be reproduced at commercial scale without losing what customers love about it?
That means formulation strategy intersects with:
Scale-up
Manufacturing controls
Raw-material variability
Batch specifications
Quality systems
Stability
Packaging
Production yield
The laboratory prototype is only the beginning.
A commercially valuable product has to survive manufacturing.
Scale-Up Risk Becomes More Important as the Brand Grows
Making 500 grams in a laboratory and making 5,000 kilograms in manufacturing are physically different processes.
Mixing efficiency, heat transfer, shear, cooling, hydration, aeration, and ingredient addition can all behave differently as batch size changes.
This is why a formula that performs beautifully at bench scale still needs a thoughtful scale-up and manufacturing-validation process.
For an early-stage founder, this may feel like a technical issue.
For an investor looking at rapid growth, it is also a supply issue.
If the brand suddenly needs to increase production tenfold, can it?
And can it do so without changing the product customers already love?
That is a formulation question with a financial consequence.
Formula Consistency Is Part of Brand Equity
Consumers expect the moisturizer they buy six months from now to behave like the moisturizer they loved today.
Changes in:
Viscosity
Color
Odor
Dispensing
Texture
Absorption
Finish
can undermine trust even when the formula technically remains within safety specifications.
That consistency becomes especially important for hero products.
Once a brand builds customer loyalty around a particular sensory experience, preserving that experience has commercial value.
For an acquirer, the question is not only whether the formula can be made.
It's whether it can be made consistently enough to preserve the brand promise.
Gross Margin Starts Inside the Formula
Investors care deeply about margins because fixing poor product-level economics after a company is large can be difficult without changing the customer experience.
Beauty-industry M&A commentary has recently highlighted strong gross margins as especially attractive because strategic buyers may find operating-cost synergies after acquisition, while repairing structurally weak product margins can be much harder without compromising quality.
That makes formulation part of financial strategy.
A formula may contain:
An unnecessarily expensive active
Too many redundant extracts
An unusually costly fragrance
A difficult-to-source emulsifier
A raw material with a high MOQ
An active system that increases processing cost
Each individual decision may look small.
Together, they determine COGS.
Cosmeta's article on How to Price a Skincare Product examines this connection from the pricing side. For investors, the same issue appears as margin quality.
High COGS Is Not Automatically a Bad Formulation Strategy
A luxury serum can justify expensive ingredients.
A highly differentiated clinical product may need costly technologies.
A sophisticated sunscreen may be expensive to manufacture.
The problem is not high COGS by itself.
The question is whether the COGS supports:
The retail price
Gross margin
Channel structure
Product performance
Consumer expectations
Competitive positioning
A $15 product cost inside a $150 high-retention prestige treatment may be completely rational.
The same $15 cost inside a $38 product expected to support wholesale and distributor margins may be much harder.
Investors care about economics in context.
Cost Optimization Should Not Destroy the Product
This is one of the formulation risks I think becomes particularly important after investment or acquisition.
The new owner sees an opportunity:
Take $1 out of COGS across one million units and we save $1 million.
Mathematically, that is compelling.
But where does the dollar come from?
If it comes from:
Better purchasing
Scale
Supplier negotiation
Packaging simplification
Manufacturing efficiency
excellent.
If it comes from replacing the emollient system that created the product's signature skin feel, the savings may cost more than they return.
The best formulation strategy gives an investor room to optimize economics without accidentally optimizing away the reason people repurchase the product.
That is a very different form of value creation.
Formula Ownership Makes Cost Optimization More Intelligent
Owning the quantitative formula gives the company a map.
If COGS needs to improve, the development team can identify:
Which raw materials drive the greatest cost
Which ingredients are critical to claims
Which ingredients drive sensory
Which ingredients are commercially redundant
Which supplier technologies might have alternatives
Where scale can improve purchasing economics
Without quantitative visibility, cost optimization becomes much more difficult.
You may know the product costs $8.
You don't necessarily know why it costs $8.
That distinction becomes important during investment, scale, and acquisition.
Strong Formulation Strategy Creates Product-Line Leverage
Investors do not always want one successful SKU.
They want to understand whether the company has room to grow.
A strong formulation strategy can create a product platform rather than a disconnected collection of launches.
A barrier-care brand, for example, might establish a coherent development philosophy around:
Gentle cleansing
Physiological lipids
Hydration
Barrier-supportive actives
Sensitive-skin sensory targets
That framework can support future products while maintaining a recognizable technical identity.
Likewise, a hair brand might own a meaningful conditioning platform that can move across masks, leave-ins, scalp products, and styling.
The underlying formulation thinking becomes reusable.
That is strategically different from launching whatever ingredient happens to be trending next.
Product Architecture Can Be More Valuable Than One Hero Ingredient
Beauty brands often build launches around ingredients.
Niacinamide.
Peptides.
Ceramides.
Bakuchiol.
Vitamin C.
Those ingredients may help consumers understand the product.
But most are widely available.
The investor question eventually becomes:
What has the brand built around them?
The defensible value may lie in:
The combination
Ingredient forms
Quantitative architecture
Delivery
Sensory system
Claims evidence
Packaging
Consumer target
Manufacturing know-how
A commodity ingredient can still live inside a very differentiated product.
That is why ingredient novelty and product defensibility are not the same thing.
Clinical Testing Can Strengthen the Product Story
Current beauty investors are showing increased interest in clinically substantiated products and brands that can demonstrate product efficacy rather than relying exclusively on broad marketing claims.
That doesn't mean every cosmetic brand needs a pharmaceutical-style clinical program.
Testing should follow the claims and commercial strategy.
Depending on the product, evidence may include:
Instrumental hydration measurements
TEWL
Consumer-use studies
Dermatologist evaluation
Imaging
Color measurements
Wrinkle analysis
Other claim-specific methods
Finished-product testing can be particularly useful because it evaluates the product the consumer is actually using rather than extrapolating from ingredient literature alone.
That can make the difference between:
“This ingredient has research.”
and
“This product demonstrated this outcome under these test conditions.”
Those are different levels of substantiation.
Ingredient Research Is Not Finished-Product Proof
This distinction matters during diligence too.
A supplier may provide an excellent clinical study on a proprietary peptide.
That supports the ingredient.
It does not automatically prove that every finished product containing the peptide will reproduce the same outcome.
The formula may use:
A different concentration
A different vehicle
A different target population
Different supporting ingredients
A different application frequency
Finished-product substantiation can therefore become another layer of defensibility.
A brand isn't simply repeating the ingredient supplier's story.
It has evidence around its own product.
What Due Diligence May Reveal About a Formulation Strategy
By the time a serious investor or acquirer begins due diligence, formulation questions become less theoretical.
They may want to understand:
Who owns each formula?
Are the quantitative formulas documented?
Are important supplier technologies identified?
Are manufacturing instructions and finished-product specifications available?
Are formulas stable in their commercial packaging?
Have relevant claims been substantiated?
Are there raw materials with unusual sourcing risk or high minimums?
Are any products dependent on one manufacturer or one supplier?
Can production scale without materially changing the product?
Are formulas compliant with the markets where the business intends to grow?
The exact diligence process varies by transaction, but the underlying objective is consistent: identify risks that could reduce the value, transferability, or future growth of the business.
Formula ownership is particularly relevant here. Cosmeta's existing guidance makes the distinction clearly: private-label formulas are generally controlled by the manufacturer, while custom formulations may become a brand asset when the development agreement explicitly transfers ownership.
Documentation Can Be an Asset Too
A formulation strategy becomes much stronger when the technical knowledge surrounding the product is organized.
A brand may have an excellent formula, but if important information exists only in old emails, supplier conversations, or one manufacturer's internal files, the business is harder to transfer.
Useful records can include:
Quantitative formulas
Raw-material specifications
Supplier information
Certificates and technical documentation
Finished-product specifications
Stability records
Packaging compatibility results
Microbial and challenge-testing results
Claims substantiation
Scale-up records
Manufacturing updates
Approved formula revisions
This is not exciting founder work.
It can become extremely important company-building work.
An investor is not only evaluating whether today's products work. They may also be evaluating whether the organization knows why they work and can continue making them without relying on institutional memory.
Version Control Matters More Than Founders Expect
Formulas evolve.
A supplier changes.
A preservative system gets adjusted.
A fragrance is modified.
The manufacturer improves processing.
An active is increased.
Packaging changes.
All of those can be completely reasonable.
The problem begins when no one can confidently answer:
Which formula is the current commercial formula?
For a small founder-led company, that may initially feel manageable because the founder knows what happened.
At acquisition scale, that is not enough.
A technically mature brand should be able to identify the current approved formula and understand the history of meaningful changes.
This is one of the less visible signals that a business is ready to scale beyond its founder.
Supply-Chain Risk Lives Inside the Formula
Ingredient sourcing can become a meaningful diligence issue, particularly as beauty supply chains deal with pricing volatility, tariffs, international sourcing, and specialized technologies. Recent industry reporting has highlighted how global ingredient sourcing can expose brands to changing costs and supply constraints.
A formula may depend on:
One patented active from one supplier
A specialty botanical from one geography
A custom fragrance
A material with a 16-week lead time
A high-MOQ biotech ingredient
A raw material available only through one distributor
A component vulnerable to regulatory change
None of those automatically makes the product unattractive.
Investors will care about whether the company understands the dependency.
A single-source ingredient may be essential to the product's differentiation.
Fine.
Then the company should know that and manage it intentionally.
The risk is not always having a sole-source technology.
The risk is discovering you had one only after the supplier can no longer deliver it.
Ingredient Exclusivity Can Create a Moat, but It Can Also Create Dependence
Exclusive ingredients, proprietary complexes, and biotechnology platforms can strengthen a product story.
They may create genuine differentiation.
Beauty companies have even pursued closer relationships or acquisitions of ingredient suppliers to secure innovation, supply, and margin advantages.
But exclusivity has another side.
If the brand's hero product depends completely on a supplier technology it does not control, investors may want to understand:
How secure is access?
Is there an agreement?
Can the supplier sell the technology to competitors?
What happens if pricing changes?
What happens if the material is discontinued?
Can the formula survive without it?
That doesn't diminish the value of proprietary supplier technologies.
Some of the most interesting cosmetic innovation comes from them.
It simply means ingredient differentiation and supply-chain resilience need to be considered together.
Investors Do Not Necessarily Need the Formula to Be Patentable
This is another misconception worth clearing up.
A proprietary cosmetic formula does not automatically need a patent to have business value.
Patentability requires specific legal criteria, and many excellent cosmetic formulations would not qualify or would not justify the cost and disclosure involved in patenting them.
Trade-secret protection, contractual ownership, proprietary know-how, trademarked technologies, clinical data, distinctive sensory performance, and brand equity can all contribute to defensibility.
The investor question is broader than:
“Do you have a patent?”
It is:
“What makes this difficult to replace?”
The answer may involve intellectual property.
It may also involve product performance, customer loyalty, formulation know-how, supply relationships, or the speed at which the company can continue innovating.
A Formula Can Function as a Trade Secret
A privately controlled quantitative formula can potentially be treated as confidential business information and protected through appropriate contracts and information controls.
The important concept is not secrecy for its own sake.
It is control.
If the full formula is published publicly, broadly distributed without confidentiality protections, or never contractually transferred to the brand, the intellectual-property position becomes different.
Founders planning for investment should therefore consider early:
Who has access to the formula?
What do the development contracts say?
What do manufacturing agreements say?
Are confidentiality provisions appropriate?
Is documentation controlled?
Those decisions are easier to establish during development than to reconstruct when an investor asks several years later.
A Brand Does Not Need to Own Every Formula to Be Investable
This is important because the opposite position would be misleading.
Many successful beauty brands have been built using private label, manufacturer-owned formulas, licensed technologies, or combinations of custom and existing products.
Formula ownership is one potential advantage.
It is not a prerequisite for a valuable beauty company.
An investor may be completely comfortable with manufacturer-controlled formulas if:
The relationship is contractually secure
Margins are strong
Products are differentiated in other ways
Supply is reliable
The brand has powerful customer loyalty
Manufacturing terms are favorable
Transfer risk is understood
The issue is transparency.
A brand should know what it owns and what it does not.
That is considerably stronger than discovering the answer during acquisition diligence.
Private Label and Custom Formulation Signal Different Strategies
Private label can be a very rational way to build a beauty business.
It offers advantages such as:
Lower upfront development cost
Faster commercialization
Established manufacturing
Reduced technical development burden
For a brand testing a category or prioritizing speed, that may be exactly the right choice.
Custom formulation becomes more strategically attractive when the brand needs more control over:
Performance
Sensory profile
Ingredient percentages
Technology
Claims
Certification
Product differentiation
Manufacturing flexibility
Formula ownership
The investor does not necessarily care that one route sounds more sophisticated.
They care whether the route aligns with the company's competitive strategy.
Cosmeta's comparison of private label vs. custom formulation makes the same distinction: custom formulation can create a formula asset, while private label prioritizes speed and simplicity.
The Better Question Is Whether the Product Architecture Supports the Company Strategy
Consider two hypothetical brands.
Brand A wins through extraordinary storytelling, community, distribution, and speed. Its products are well-executed but not highly proprietary.
Private label may be perfectly compatible with that strategy.
Brand B positions itself as a science-driven skincare company whose valuation depends heavily on proprietary performance and product innovation.
If Brand B does not own or control any of the formulation architecture behind that promise, investors may ask harder questions.
Neither business model is inherently superior.
The important thing is alignment.
Your formulation strategy should support the reason your company deserves to exist.
Claims Risk Can Become Investment Risk
Claims are another area where formulation and business diligence meet.
A product may have fantastic consumer reviews and still create risk if its claims substantially exceed the evidence supporting them.
That can become particularly important with products positioned around:
Acne
Eczema
Hair growth
Hormones
Rosacea
SPF
Wound healing
Structural changes to skin
Medical or therapeutic outcomes
A cosmetic company needs to maintain the distinction between cosmetic claims and drug claims where applicable.
Investors may also want confidence that meaningful efficacy statements can be substantiated.
This is one reason finished-product testing can add value beyond marketing.
It helps connect the claim directly to the commercial product.
Regulatory Readiness Supports Scalability
A formulation can be successful in one market and still require changes for another.
Ingredient restrictions, labeling, claims, product classification, required safety documentation, and other requirements differ across jurisdictions.
A brand planning international expansion needs to know whether its hero products can actually travel.
That may include questions such as:
Are any ingredients restricted in target markets?
Will the preservative system work globally?
Does the formula meet intended retailer standards?
Can the claims be maintained?
Will labeling need to change?
Does a reformulation risk changing what customers love?
For investors, global expansion is far more credible when the products themselves are capable of supporting it.
Sustainability Can Become a Formulation and Investment Issue Too
Sustainability is no longer confined to packaging copy.
A company's ingredient sourcing, manufacturing footprint, formula concentration, water use, packaging, refill strategy, and supply-chain choices can all become part of the broader business story.
But investors are unlikely to benefit from sustainability claims that weaken product performance or introduce avoidable operational risk.
The same principle applies here that Cosmeta uses in Clean Beauty 2.0:
Product philosophy has to coexist with performance and commercial viability.
A formulation strategy built around sustainability should be able to explain the trade-offs rather than rely on vague environmental language.
Strong Formulation Strategy Can Reduce the Cost of Future Innovation
There is another benefit that may not appear immediately in due diligence.
A company that understands its own formulation architecture can innovate faster.
It already knows:
Which ingredient systems work
Which sensory targets define the brand
Which suppliers perform reliably
Which technologies consumers respond to
Which manufacturing constraints exist
Which claims can be supported
Future product development starts from a platform instead of zero.
This can reduce technical risk and make R&D spending more productive.
For an investor planning to grow a brand's assortment, that capability matters.
A brand with one accidental hit is different from a company with a repeatable product-development engine.
A Product Pipeline Should Have More Logic Than “We Need More SKUs”
Investors often want growth.
That does not mean launching endlessly.
A strong formulation strategy can show how future products expand the brand's core advantage rather than dilute it.
For example, a barrier-focused brand might logically expand from moisturizer into:
Cleanser
Serum
Body care
Hand care
Scalp care
if each product reflects the same technical philosophy.
A brand known for one proprietary peptide technology might extend the platform into multiple targeted applications.
That is different from launching whatever ingredient trend is currently growing on TikTok.
A product pipeline becomes more credible when each SKU strengthens the same strategic territory.
Too Many SKUs Can Be a Formulation Warning Sign
An overextended assortment can create hidden complexity.
Every additional formula potentially introduces:
More raw materials
More supplier relationships
More stability programs
More packaging
More manufacturing setups
More inventory
More quality documentation
More regulatory maintenance
A founder may see twenty SKUs as growth.
An investor may also see working capital and operational complexity.
This does not mean small assortments always win.
It means the formulation strategy should understand the cost of complexity.
Sometimes fewer, stronger products create a more attractive business.
Reformulation Risk Should Be Understood Before an Acquisition
Acquirers sometimes want to change products after purchase.
Perhaps they want to:
Improve gross margin
Meet global regulations
Remove an ingredient
Change a supplier
Update packaging
Expand manufacturing capacity
Meet a retailer standard
If the formula is well documented and owned, those changes can be approached deliberately.
If the product is essentially a black box controlled by one manufacturer, reformulation may become much more difficult.
The danger is not simply technical failure.
It is changing the experience customers already associate with the brand.
This is why preserving sensory benchmarks and finished-product specifications can matter during ownership transitions.
Hero Products Deserve Disproportionate Protection
Most beauty brands do not generate equal revenue from every SKU.
One or two products often carry a disproportionate share of sales, reviews, awareness, and customer acquisition.
Those products deserve disproportionate technical attention.
For a hero SKU, I would want especially strong confidence around:
Formula ownership or contractual control
Quantitative documentation
Raw-material continuity
Stability
Packaging compatibility
Manufacturing scalability
Finished-product specifications
Claims support
Backup plans
The product most responsible for the company's value should not be the product with the least technical redundancy.
The Best Formulation Strategy Reduces Key-Person Risk
Founder-led beauty brands often rely heavily on the founder's personal knowledge.
That can be a strength during the early years.
Eventually it can become risk.
If the founder is the only person who knows:
Why the formula changed
Which supplier is acceptable
What the benchmark should feel like
Which manufacturer adjustment caused problems
Which claims were tested
Why one ingredient cannot be substituted
then the business is dependent on that person remaining involved forever.
Investors often think about key-person risk more broadly across a company.
Technical documentation can reduce the formulation version of that risk.
The knowledge becomes organizational.
Acquirers Are Buying the Ability to Keep Selling the Product
This may be the simplest way to think about formulation due diligence.
An acquirer is not buying the formulas because chemistry is interesting.
They are buying the ability to keep producing and selling products consumers want.
So they need confidence that after the transaction:
The product can still be manufactured.
The product can still meet specifications.
The supply chain can still function.
Claims can still be supported.
Margins can still work.
The product can evolve when necessary.
And consumers will still recognize what they loved.
A good formulation strategy makes that future easier to believe.
What a Strong Formulation Strategy Signals
From an investor's perspective, a strong formulation strategy can signal several things at once.
The company thinks beyond launch.
Products are designed for manufacturing, margin, stability, and growth.
The company understands its assets.
Ownership and supplier relationships are clear.
The company can protect product quality.
Specifications, testing, and manufacturing controls exist.
The company has options.
It can potentially change suppliers, manufacturers, packaging, or formulation when necessary.
The company knows why its products are different.
Differentiation is more specific than generic hero ingredients.
The company can continue innovating.
Future products build from a coherent technical platform.
None of those guarantees investment.
But they make the product side of the business considerably easier to evaluate.
What Weak Formulation Strategy Can Signal
The opposite can create questions.
Potential warning signs might include:
Unclear formula ownership
No quantitative formula access
Undocumented formula revisions
Unverified claims
Poor stability documentation
Reliance on one difficult supplier without contingency planning
One manufacturer controlling all technical information
Hero products that cannot easily scale
Weak margins with no obvious optimization path
Frequent product problems
A portfolio built entirely around interchangeable trend ingredients
One issue by itself may be completely manageable.
Several together can suggest the company has grown faster than its product infrastructure.
That is fixable.
It is usually easier to fix before due diligence begins.
When Should a Founder Start Thinking About This?
Much earlier than fundraising.
The best time to create an investment-ready formulation strategy is while products are being developed.
That does not mean building the company for an exit from day one.
It means making sensible decisions that are useful whether you ever raise outside capital or not.
Own what you intend to own.
Know what you don't.
Document the current formula.
Understand your suppliers.
Build realistic margins.
Test the finished product appropriately.
Protect the hero SKU.
Keep options open.
Those practices help a bootstrapped founder too.
Investment Readiness Is Really Business Readiness
This is where the article comes full circle.
Most of the things that make formulation attractive to an investor are the same things that make the company stronger without one.
Formula ownership can improve manufacturing flexibility.
Documentation can improve quality.
Better margins create more cash.
Supply redundancy reduces disruption.
Finished-product testing improves claims credibility.
Scalable formulations support growth.
A coherent product platform makes innovation more efficient.
You do not need an investor to benefit from any of that.
Investment simply creates the moment when someone outside the company starts asking whether those foundations exist.
Key Takeaways
Investors evaluate beauty brands as businesses, not laboratories. Growth, retention, margins, distribution, leadership, and consumer demand remain critical. Current beauty M&A commentary points to strong margins, repeat purchasing, efficient growth, product differentiation, and credible value propositions as important valuation drivers.
Formulation matters because it sits underneath several of those strengths.
A strong formulation strategy can provide product differentiation, manufacturing flexibility, margin visibility, claims support, supply-chain resilience, and a platform for future innovation.
Formula ownership is valuable when it gives the brand genuine control of the quantitative formula, but ownership alone is not enough. Documentation, portability, manufacturing knowledge, specifications, testing, and supplier strategy determine how usable that asset actually is.
And no formulation strategy substitutes for consumer demand.
The strongest beauty companies connect the two: products people repeatedly want to buy and an infrastructure capable of producing those products profitably, consistently, and at scale.
Cosmeta's Perspective
I think beauty founders sometimes wait too long to think about formulation as an asset.
Early on, the formula feels like the thing you need in order to launch.
Later, it becomes part of the infrastructure of the company.
That change is important.
Once a product starts driving real revenue, questions around ownership, percentages, suppliers, manufacturing, stability, cost, and portability stop being technical details. They become business questions.
And I would not build all of that only for a hypothetical acquisition.
I would build it because control gives a founder options.
You can stay with the same manufacturer because they are excellent, not because you are trapped there.
You can keep an expensive ingredient because it creates meaningful value, not because you don't know what is driving COGS.
You can reformulate when the market changes without starting from zero.
You can show an investor exactly what the company owns.
That is the broader value of formulation strategy.
The formula isn't automatically the moat.
But when it is thoughtfully developed, owned, documented, scalable, and surrounded by real consumer demand, it can become a meaningful part of one.
Ready for the Next Step
If long-term company value matters, treat formulation decisions as business architecture from the beginning. Know what the brand owns, document the quantitative formula and testing history, understand the supply chain, and make sure the hero products can scale without losing what made consumers want them in the first place.
FAQs
-
They can, particularly when formulation is important to the company's differentiation or when a potential investor or acquirer is evaluating manufacturing dependence and intellectual property. Formula ownership can give a brand greater control and transferability, but it is only one part of the investment case. Brand equity, growth, retention, margins, distribution, and other forms of defensibility also matter. Beauty-industry reporting has specifically identified formula ownership as potentially useful for funding, growth, and exit strategy.
-
A formula can potentially function as proprietary intellectual property or confidential trade-secret information depending on the circumstances, contracts, and how it is protected. Ownership of the finished quantitative formula does not give the brand ownership of third-party patented ingredients, supplier trademarks, or proprietary technologies incorporated into it. Legal counsel should determine the specific IP position for a company or transaction.
-
Yes. Formula ownership is not a prerequisite for investment or acquisition. A private-label brand may still have highly valuable brand equity, distribution, consumer loyalty, margins, trademarks, community, or other advantages. The important issue is understanding the contractual manufacturing arrangement and any dependence or transfer restrictions before due diligence.
-
Useful records can include current quantitative formulas, formula revisions, raw-material and supplier information, finished-product specifications, stability results, packaging compatibility records, microbial or challenge-testing results, claims substantiation, manufacturing documentation, and relevant regulatory records. The exact diligence requirements will depend on the buyer or investor and the transaction.
-
There is no universal valuation formula for a cosmetic formulation. Its strategic value may increase when it contributes to meaningful product differentiation, strong margins, repeat purchase, defensible claims, manufacturing flexibility, scalability, or a broader product platform. The current beauty investment environment places particular emphasis on product differentiation, consumer retention, disciplined economics, and credible efficacy rather than novelty alone.
